
First collaboration phase with Belgian diagnostics company finalized

AcouSort has finalized the first phase of the previously announced collaboration project with a Belgian diagnostics company that develops innovative products for point-of-care testing. AcouSort has over the past months developed and now delivered the test platform based on AcouSort's technology to the Belgian company. The collaboration continues with further evaluations of the platform at the company's site. The collaboration has initially generated revenues of 29,500 Euro.

The Belgium-based company is developing a platform for point-of-care diagnostics based on whole blood, initially focusing on analysis of blood cells. In the long term, there are plans to develop the system to be able to analyze other fractions of blood samples. AcouSort has over the last months successfully developed a test platform that combines AcouSort's core technology with the Belgian company's analysis technology. With the test platform ready, the Belgian company will be able to take the next step and evaluate if AcouSort's technology for integrated blood separation will improve their system's measurement performance.

"We are very much looking forward to continue the next phase of our collaboration where the test platform will be used to evaluate possible integration of our technology into the company's innovative diagnostic instrument for point-of-care testing. We highly value these types of collaborations as they pave the way toward new OEM agreements. If the outcome of the evaluation is positive, we have good hopes that this may result in a long-term OEM collaboration," says AcouSort's CEO Torsten Freltoft.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.